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Carnitine palmitoyltransferase II deficiencyThe recent introduction of metabolic autopsy in the field of forensic science hasmade it possible to detect hidden
inherited metabolic diseases. Since the next generation sequencing (NGS) has recently become available for use
in postmortem examinations, we used NGS to performmetabolic autopsy in 15 sudden unexpected death in in-
fancy cases. Diagnostic results revealed a case of carnitine palmitoyltransferase II deficiency and some cases of
fatty acid oxidation-related gene variants. Metabolic autopsy performed with NGS is a useful method, especially
when postmortem biochemical testing is not available.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Sudden unexpected death in infancy (SUDI) is defined as a term that
has been variably used to refer to all cases of sudden and unexpected
deaths in infancy, and not just to those where the death has been attrib-
uted to sudden infant death syndrome [1]. The common causes of SUDI
are accidental death, infection, cardiovascular anomaly, child abuse and
metabolic diseases.
Fatty acid oxidation disorder (FAOD) is one type of the inherited
metabolic diseases that can lead to patient death during situations
such as long fasting or infection. Before the introduction of expanded
newborn screening by tandem mass spectrometry, FAODs account
for approximately 5% of sudden infant deaths [2–7] (Table 1). Some
patients can now be screened before the symptom is apparent,
others still may remain undetected because the screening has just
started nationwide in Japan and some disorders including carnitine
palmitoyltransferase (CPT) II deficiency are not included in the first tar-
get disease [8]. Since FAODs are functional diseases, they are not easy to
diagnose, especially during postmortem examinations. Therefore, someamoto).
. This is an open access article undercases may remain undiagnosed or may be incorrectly classified as sud-
den infant death syndrome.
The recent introduction of metabolic autopsy in the field of forensic
science has made it possible to detect hidden inherited metabolic dis-
eases [7,9]. Metabolic autopsy is the autopsy which focuses on the
inherited metabolic diseases [10]. The termmetabolic autopsy includes
microscopic examination of the liver, postmortem blood acylcarnitine
analysis and genetic analysis [7]. Since liver steatosis is often seen as a
nonspecific change in SUDI and the results of postmortem blood
acylcarnitine analysis is often modified by postmortem changes, it is
not easy to make a biochemical diagnosis [11]. Although successful ge-
netic analysis has been reported in many cases, there are about 20
FAOD-related genes and thus, surveying all of the genes using Sanger's
traditional method of “one gene, one exon at a time” is not an effective
way for analyzing these types of cases.
The next generation sequencing (NGS) has recently become avail-
able for use in postmortem examinations [12,13]. This technique
makes it possible to examine a much larger number of genes and
exons at a lower cost in addition to requiring less time than that for
the conventional Sanger's method. However, most of the studies using
these new techniques have focused on cardiac diseases and thus,
there has yet to be metabolic autopsy performed with NGS [13].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Proportion of inherited metabolic disorders among sudden unexpected death in infancy.
Number of cases Number of diagnosis Reference
58 6 (10.3%) Bennett et al. [2]
79 3 (3.8%) Lundemose et al. [3]
418 14 (3.3%) Boles et al. [4]
7058 66 (0.93%) Chace et al. [5]
247 3 (1.2%) Wilcox et al. [6]
30 1 (3.3%) Yamamoto et al. [7]
Table 3
Gene summary.
Gene OMIM Exon Disease OMIM
SLC22A5 603377 10 Primary carnitine deficiency 212140
CPT1A 600528 19 CPT I deficiency 255120
CPT2 600650 5 CPT II deficiency 608836
600649
255110
SLC25A20 613698 9 CACT deficiency 212138
ACADVL 609575 20 VLCAD deficiency 201475
ACADM 607008 12 MCAD deficiency 201450
ACADS 606885 10 SCAD deficiency 201470
HADHA 600890 20 LCHAD, MTP deficiency 609016 (LCHAD)
HADHB 143450 16 MTP, LCKAT deficiency 609015 (MTP)
HADH 601609 8 HAD deficiency 231530
ETFA 608053 12 MAD deficiency 231680
ETFB 130410 6
ETFDH 231675 13
CPT; carnitine palmitoyltransferase, CACT; carnitine-acylcarnitine translocase, VLCAD;
very-long-chain acyl-CoA dehydrogenase, MCAD; medium-chain acyl-CoA dehydroge-
nase, SCAD; short-chain acyl-CoA dehydrogenase, LCHAD; long-chain 3-hydroxyacyl-
CoA dehydrogenase, MTP; mitochondrial trifunctional protein, LCKAT; long-chain 3-
ketoacyl-CoA thiolase, HAD; 3-hydroxyacyl-CoA dehydrogenase, MAD; multiple acyl-
CoA dehydrogenase.
27T. Yamamoto et al. / Molecular Genetics and Metabolism Reports 5 (2015) 26–32Therefore, the aim of our current study is to detect FAOD-related
gene variants among sudden death cases. As far as we know, this is
the first metabolic autopsy performed with NGS.
2. Materials and methods
2.1. Subjects and target sequence
A total of 15 SUDI cases, all of which did not have any characteristic
appearance and remained undiagnosed after macroscopic examination,
were analyzed at theDepartment of Forensic Pathology atNagasakiUni-
versity (Table 2; 11 males, 4 females, age range; 0 days to 11 months).
All cases were born before 2014 and none of them were screened by
tandem mass spectrometry.
2.2. Extraction of genomic DNA and genetic analysis
Genomic DNA was isolated from blood leukocytes with the QIAamp
DNA BloodMini Kit (Qiagen, Tokyo, Japan) in accordancewith theman-
ufacturer's standard methods. A custom-made HaloPlex Target Enrich-
ment System (Agilent Technologies, Santa Clara, CA) was designed to
capture the coding exons of the 13 genes targeted to the FAODs
(Table 3). The sequencing was performed on an Illumina MiSeq
(Illumina, San Diego, CA).
The sequencing readsweremapped on the hg19 human genome se-
quence using Novoalign version 3.02.12 software (Novocraft, Petaling
Jaya, Selangor, Malaysia). Single nucleotide variations and small inser-
tions/deletions were detected using the Genome Analysis Toolkit [14]
and annotated using the ANNOVAR software package [15].
Filtering of the variant data was performed as described below.
Using the gene information of the GENCODE version 19 [16], single nu-
cleotide variations causing non-synonymous, splice site, or nonsense
substitutions and insertions/deletions occurring in the coding regionsTable 2
Case summary.





1 0 d F Unknown None specific change Negative
2 0 d M Unknown None specific change Negative
3 2 d M Pneumonia Not analyzed Negative
4 22 d M Unknown None specific change Negative
5 2 m M Acute respiratory
infection
Not analyzed Negative
6 3 m M SIDS None specific change Negative
7 4 m M SIDS None specific change Moderate
8 5 m M Pneumonia Not analyzed Negative
9 5 m M Unknown Not analyzed Negative
10 7 m M SIDS Not analyzed Negative
11 8 m M Reye's-like syndrome Not analyzed Moderate
12 8 m M SIDS Not analyzed Negative
13 10 m F Unknown None specific change Moderate
14 11 m F Acute encephalopathy Not analyzed Negative
15 11 m F Reye's-like syndrome Long-chain fatty acid
defect
Distinctive
SIDS; sudden infant death syndrome, d; day, m; month, M; male, F; female.or the splice sites were retrieved. To identify putatively pathogenic var-
iants, we retained variants with allele frequencies equal to or less than
0.5% in any of the ethnic subgroups found in the various databases.
These included variants listed in the Japanese 1200 exomes from the
Human Genetic Variation Database (http://www.genome.med.kyoto-
u.ac.jp/SnpDB/), the 1000 Genomes Project [17] and the 6500 control
exomes from the NHLBI GO Exome Sequencing Project (ESP) (http://
evs.gs.washington.edu/EVS/).
The detected variants were confirmed by the traditional Sanger's
method. Each of the exons was amplified, and then examined by poly-
merase chain reaction (PCR). All reactions were performed in a 25-μL
volume containing 12.5 μL of PrimeSTAR Max Premix (2×) (Takara,
Otsu, Japan), 0.4 μM each of the primers and 200 ng of template DNA
under the following conditions: 98.0 °C for 1 min, (98.0 °C for 10 s,
54.0 °C for 5 s, 72.0 °C for 30 s) for 30 cycles, and 72.0 °C for 5 min.
The products were sequenced using the BigDye® Terminator v3.1
Cycle Sequencing Kit (Applied Biosystems, Foster City, CA) on Applied
Biosystems 3130 DNA Analyzer (Applied Biosystems) in accordance
with the manufacturer's instructions. The sequence from both strands
was visually inspected in order to confirm the substitution.
2.3. Analysis of the amino acid residues
SIFT (http://sift.jcvi.org/) and PolyPhen-2 (http://genetics.bwh.
harvard.edu/pph2/index.shtml/) were used to predict whether each
amino acid substitution would affect the function of each protein.
These substitutions were also aligned across species (https://genome.
ucsc.edu/cgi-bin/hgGateway/).
2.4. Postmortem blood acylcarnitine analysis by tandemmass spectrometry
Whole blood samples were blotted onto one spot on a Guthrie card
and then subjected to acylcarnitine analysis by tandem mass
spectrometry.
2.5. Extraction of genomic DNA and performance of mutational analysis in
the other family members
Genomic DNA was purified from buccal cell swabs in accordance
with standard methodology. PCR was performed using the previously
discussedmethod. Genomic DNA samples from the parents and the sis-
ter were examined for the presence or absence of the CPT2mutation.
28 T. Yamamoto et al. / Molecular Genetics and Metabolism Reports 5 (2015) 26–322.6. Ethics
This study was approved by the Ethics Committee of the Nagasaki
University Graduate School of Medicine.
3. Case history in Case 15
The patientwas a female carried to full-termand delivered via cesar-
ean section. Her Apgar score was 6/9, birth weight was 2870 g, height
was 49.0 cm and head circumference was 34.0 cm.
At 11 months of age, she was taken to a doctor's office because of
fever and vomiting that had continued for several days. After examina-
tion, she was prescribed cephem antibiotics. During the morning of theFig. 1. Histological examination of Case 15. Steatosis was detected in the liver (A; hematoxylinnext day, however, she suddenly lost consciousness and an ambulance
was requested. By the time the emergency service personnel arrived,
she had already suffered cardiopulmonary arrest. Although cardiopul-
monary resuscitation was initiated immediately and continued until
she reached the hospital, she was pronounced dead.
The patient had never been ill until the time of her death. Family his-
tory was negative for seizures, arrhythmias and sudden death. Her par-
ents were not consanguineous.
Histological examination of the patient led to the diagnosis of
Reye's-like syndrome. The liver showed diffuse and distinctive vacuoles,
which Oil-red O staining subsequently confirmed to be the accumula-
tion of fatty acids. Oil-red O-positive vacuoles were also detected in
the kidney and heart (Fig. 1).–eosin (H.E.), B; Oil-red-O), kidney (C; H.E., D; Oil-red-O) and heart (E; H.E., F; Oil-red-O).
Table 4
Detected variants.
Case Gene AA Substitution SIFT PolyPhen-2 HGVB EXAC
5 ACADS P55L 164CNT Heterozygote Damaging 0.0 Probably D 0.993 8/8654 3/1346
6 CPT2 F383Y 1148TNA Heterozygote Tolerated 0.61 Possibly D 0.932 3/8644 1/600
7 SLC22A5 D487N 1459GNA Heterozygote Tolerated 1.0 Benign 0.001 0/121,410 1/600
14 ACADS V84M 250GNA Heterozygote Damaging 0.02 Probably D 0.997 0/6496 0/600
15 CPT2 F323fs 968_969 del TC Heterozygote
15 CPT2 V605L 1813GNC Heterozygote Damaging 0.004 Possibly D 0.885 3/8654 1/600
W; wild type, M;mutation type, AA; amino acid change, probably D; probably damaging, possibly D; possibly damaging, HGVB; Human Genetic Variation Browser, EXAC; The Exome Ag-
gregation Consortium.
29T. Yamamoto et al. / Molecular Genetics and Metabolism Reports 5 (2015) 26–324. Results
4.1. Target sequence of sudden death cases
Targeted resequencing revealed themean coverage of the coding se-
quence in the target genes was 155.4 reads, with an overall average
gene level coverage at ≥10 reads of 90.9%.
Table 4 shows the detected variants found during the filtering steps.
After the filtering, only six variants remained.4.2. Genetic analysis in Case 15
Among the detected variants, only Case 15 was found to have two
pairs of heterozygous deletion (c.968_969 del TC, p.F323fs) and substi-
tution (c.1813GNC, p.V605L) in the CPT2 gene, all of which were con-
firmed by Sanger's sequencing (Fig. 2). Pedigree analysis confirmed
that the deletionwas transmitted fromher father while the substitution
was from her mother (Fig. 2). The c.1813GNC (p.V605L) substitution
has been previously reported in a Japanese CPT II deficiency patient
[21]. This was detected in 3 alleles among the 8654 East Asian control
alleles (minor allele frequency: 0.0004, The ExomeAggregation Consor-
tium) and in 1 allele out of the 600 Japanese control alleles (minor allele
frequency: 0.002, Human Genetic Variation Browser). Results also pre-
dicted there would be an effect on the function of the protein, with a
SIFT of 0.004, which indicated damaging and a PolyPhen-2 of 0.885,Fig. 2. Sequencing analysis in Case 15. Case 15 had two pairs of heterozygous deletions (c.968_9
deletion (c.968_969 del TC) while the mother had a heterozygous substitution (c.1813GNC).which indicated possibly damaging. An examination of species ranging
from zebrafish to human showed the substitution was conserved
(Fig. 3).
Analysis also showed there were two homozygous substitutions
(c.1055TNG, p.F352C and c.1102GNA, p.V368I) in the CPT2 gene. Since
these two substitutions are common genetic polymorphisms [18–22],
they were excluded from the targeted NGS analysis.
4.3. Other genetic substitutions
There were four other substitutions found in four different cases.
Case 5 had the substitution ACADS-P55L (c.164CNT), Case 6 had CPT2-
F383Y (c.1148TNA), Case 14 had ACADS-V84M (c,250GNA), and Case
7 had SLC22A5-D487N (c.1459GNA) (Table 4). The former three were
heterozygous substitutions that according to SIFT or PolyPhen-2 were
predicted to affect the function of the protein. An examination of species
ranging from zebrafish to human showed the substitution was con-
served (Fig. 3).
4.4. Acylcarnitine analysis in Case 15
We performed acylcarnitine analysis of the postmortem whole
blood samples using tandem mass spectrometry. Free carnitine was
181.24 μM, which was increased as compared to the normal range
(b60 μM), but which was within the postmortem reference value69 del TC) and substitutions (c.1813GNC) in the CPT2 gene. The father had a heterozygous
Table 5
Acylcarnitine profile in Case 15.
C0 C2 C5 C16 C18 C18:1 C18:2
Case 15 181.24 4.65 1.51 4.13 2.3 4.39 0.97
PRV 422.59 147.13 1.5 3.495 2.495 3.095 0.925
NR 60.0 45.0 1.0 7.0 2.1 3.2 0.8
PRV; postmortem reference value, NR; normal range.
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b1.0 μM, postmortem reference value: b1.5 μM). There was also an in-
crease in the C16, C18, C18:1 and C18:2-acylcarnitine (Table 5). The
ratio of [C16 + C18:1] to C2 was as high as 1.83, which suggests that
Case 15 had either a CPT II or carnitine–acylcarnitine translocase
deficiency.5. Discussion
Aftermany research studies and case reports examined postmortem
samples [2–4,23–28], in 2001, Chace et al. performed a large-scale study
of FAODs inwhich they analyzed postmortemblood samples by tandem
mass spectrometry [5]. In our previous study, we also performed post-
mortemacylcarnitine analyses,which subsequently led to our discovery
of other FAODs cases [7]. Due to postmortem changes, the interpreta-
tion of the postmortem acylcarnitine analysis is sometimes not easy.
Table 6 shows our in-house data for our postmortem acylcarnitine anal-
ysis. Based on our analytical findings, it was possible to definitively diag-
nose a CPT II deficiency case, which we reported in our previously
published study [7]. In the two false-positive cases that we observed,
we found therewere increases in the long-chain acylcarnitine in the ab-
sence of any genetic abnormality. The C16, C18, C18:1 and C18:2-
acylcarnitine values in the present case were much lower than that of
not only our definitively diagnosed case, but also the two false-
positive cases.
Definite diagnoses of FAODs can be made by either a genetic or an
enzyme analysis. The relationship between SUDI and FAODs was first
discussed in detail in the 1990's [24,29,30]. After Bennett and Powell re-
ported finding SUDI cases with an A985G mutation of the medium-
chain acyl-CoA dehydrogenase (MCAD) deficiency, they recommended
genetic analysis for SUDI be performed [2]. Unfortunately, this study
only targeted one particular substitution and did not cover any of the
other candidate genes. However, it should be noted that the number
of candidate genes for FAODs is approximately 20 genes and thus, post-
mortem genetic screening is not really practical.
Recently, NGS has been developed and is more widely used, espe-
cially in the field of sudden cardiac death [12,13]. This technique
makes it possible to examine a larger number of genes and exons at a
lower cost, in addition to requiring a smaller amount of time compared
to the conventional Sanger's method [13]. Unlike that for clinical pa-
tients, there is a lack of information and no definitive clinical symptoms
for sudden death cases. Thus, there are numerous candidate genes that
could be responsible for sudden death cases.
In our current study, we used NGS to perform target exon sequenc-
ing, in addition to conducting postmortem comprehensive genetic
screening for FAODs. As far aswe know, this is the first study to examine
metabolic autopsy performed with NGS.
In most of the cases, the sequence covered more than 90% of the
targeted exons. False-positives and false-negatives were rare. After ex-
cluding the variants that have been reported elsewhere, there were
six substitutions and deletions remaining. Because the majority of the
FAODs are inherited in an autosomal recessive manner, we chose the
one case that had at least two pairs of the heterozygous variant (CaseFig. 3. Sequence alignment between species. Except for SLC22A5-D487N, the substitutions
were highly conserved between the species.
Table 6
The comparison with other postmortem samples.
C0 C2 C5 C16 C18 C18:1 C18:2
Case 15 181.24 4.65 1.51 4.13 2.3 4.39 0.97
DD 69.46 8.5 0.13 7.41 5.29 6.79 1.64
FP 1 147.82 96.45 4.29 13.65 6.74 8.99 1.23
FP 2 127.4 35.25 1.97 6.13 3.74 3.87 1.55
DD, definitively diagnosed case, FP; false-positive case.
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TC, p.F323fs) and substitution (c.1813GNC, p.V605L) in the CPT2 gene.
Sanger's methodwas used to confirm these variants. The former variant
was inherited fromher father and caused a frameshift, thereby resulting
in an immature protein. The latter variant was inherited from her
mother and has been previously found and reported in a Japanese CPT
II deficiency patient [21]. SIFT and PolyPhen-2 classified the function
of the protein as damaging. Our analyses additionally showed that the
amino acid was conserved between the species examined. Thus, when
taken together, these genetic analyses demonstrated that this patient
had a CPT II deficiency.
There were four cases with other variants, each of which had a het-
erozygous substitution. The substitution in Case 5 was ACADS-P55L
(c.164CNT), in Case 6 was CPT2-F383Y (c.1148TNA), in Case 14 was
ACADS-V84M (c.259GNA) and in Case 7 was SLC22A5-D487N
(c.1459GNA). Because the substitution of CPT2-F383Y has also been
shown to cause decreases in the CPT II activity and been reported in a
CPT II deficiency patient [8,19–21,31], even in the heterozygous F383Y
mutation state [21,32,33], the heterozygous CPT2-F383Y mutation
could be a cause of sudden death. While the postmortem acylcarnitine
analysis in our current case did not suggest any CPT II deficiency, it is
possible that Case 6 might have been affected by the mutation.
The substitutions of ACADS are controversial. ACADS-P55L was de-
tected in 8 alleles among the 8654 East Asian control alleles (minor al-
lele frequency: 0.0009, The Exome Aggregation Consortium) and in 3
alleles out of the 1346 Japanese control alleles that were examined
(minor allele frequency: 0.002, Human Genetic Variation Browser).
ACADS-V84Mwas neither detected in the 6496 East Asian control alleles
(The Exome Aggregation Consortium) nor in the 600 Japanese control
alleles (Human Genetic Variation Browser). The SIFT scores for these
two ACADS substitutions were classified as damaging, with both substi-
tutions conserved between species. It has been reported that ACADS-
P55L decreases the enzyme activity of SCAD [34]. Although the final di-
agnoses in Case 14 and Case 5 were acute encephalopathy and respira-
tory infection, respectively, it cannot be denied that these substitutions
could have potentially affected the enzyme activity to a greater or lesser
extent. Thus, the possibility exists that individuals with rare variants are
susceptible to environmental stress. However, MCAD can compensate
for the SCAD enzyme deficiency because of the overlap in the substrate
specificity [35] and the substitution may not have a major effect to the
death. Further accumulation of the genetic data will be necessary in
order to link these rare variants and SUDI.
Even though SLC22A5-D487N was not detected in the 121,410 con-
trol alleles (The Exome Aggregation Consortium), it was detected in 1
allele out of the 600 Japanese control alleles (minor allele frequency:
0.002, Human Genetic Variation Browser). The SIFT score was classified
as tolerated while the PolyPhen-2 was classified as benign. Since amino
acid position 487 is asparagine in X. tropicalis and zebrafish, this substi-
tution might not affect the activity of this gene.
In the current study, our use of NGS led to finding a case of com-
pound heterozygote CPT II deficiency. Furthermore, we additionally
found a case of heterozygote CPT II deficiency-related gene variant
and two cases of SCAD deficiency-related variants. It is true that the
cost of NGS is still higher than postmortem blood acylcarnitine analysis,
but these variants would not have been detected without the use of
NGS. Thus, metabolic autopsy performed with NGS is a useful method,especially when postmortem blood acylcarnitine analysis is not avail-
able. These findings suggest that metabolic autopsy should be per-
formed in all cases of sudden death.
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